[The content of this article has been produced by our advertising partner.]
When Jiang Bo took up the helm as CEO of Clarity Medical Group (1406.HK) last year, the Hong Kong-listed specialist eye care provider was mired in severe financial losses and, more importantly, a history of governance issues.
These issues triggered a trading suspension and the creation of two special investigation committees to examine them.
Now emerging from its most difficult period, Clarity has a 20/20 vision for…
